Drug intelligence / Profile preview

[225Ac]Ac-mcp-IgG4

Development stage
Discontinued
Lead developer
Tri-Institutional Therapeutics Discovery Institute
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

[225Ac]Ac-mcp-IgG4 is a radiolabeled isotype control antibody utilized in preclinical radioimmunotherapy research. It consists of a non-specific human or murine immunoglobulin G4 (IgG4) monoclonal antibody conjugated to the alpha-emitting radioisotope Actinium-225 ($^{225}$Ac) via the macrocyclic chelator MACROPA (mcp). In the context of targeted alpha therapy studies, such as those evaluating agents against Delta-like ligand 3 (DLL3), this construct serves as a negative control to differentiate the therapeutic efficacy of target-specific binding from the non-specific effects of systemic radiation and the pharmacokinetic behavior of the IgG4 scaffold. Actinium-225 provides high-linear energy transfer (LET) alpha particles that induce complex DNA double-strand breaks, while the MACROPA chelator ensures stable complexation of the radionuclide to the antibody.

Other names
Actinium-225-mcp-IgG4Actinium225-mcp-IgG4Actinium 225-mcp-IgG4225Ac-MACROPA-IgG4Actinium-225-labeled IgG4 isotype controlActinium225-labeled IgG4 isotype controlActinium 225-labeled IgG4 isotype control
02

Targets

DNA

Beyond the preview

Go deeper on [225Ac]Ac-mcp-IgG4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [225Ac]Ac-mcp-IgG4.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call